{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan L"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["188-198"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11387002"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(4)"],"pubmed_abstract":["Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated or mutated splicing factors, or genetic alterations in splicing-regulatory <i>cis</i>-elements. Targeting individual altered splicing events associated with cancer-cell dependencies is a potential therapeutic strategy, but several technical limitations need to be addressed. Patient-derived organoids are a promising platform to recapitulate key aspects of disease states, and to facilitate drug development for precision medicine. Here, we report an efficient antisense-oligonucleotide (ASO) lipofection method to systematically evaluate and screen individual splicing events as therapeutic targets in pancreatic ductal adenocarcinoma organoids. This optimized delive"],"journal":["Nucleic acid therapeutics"],"pubmed_title":["Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids."],"pmcid":["PMC11387002"],"funding_grant_id":["F30 CA271804","T32 GM008444","P30 CA045508","P01 CA013106"],"pubmed_authors":["Danielsen M","Kral AJ","Schafer B","Krainer AR","Wan L","Sudheendran K","Caruthers MH","Voss D"],"additional_accession":[]},"is_claimable":false,"name":"Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids.","description":"Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated or mutated splicing factors, or genetic alterations in splicing-regulatory <i>cis</i>-elements. Targeting individual altered splicing events associated with cancer-cell dependencies is a potential therapeutic strategy, but several technical limitations need to be addressed. Patient-derived organoids are a promising platform to recapitulate key aspects of disease states, and to facilitate drug development for precision medicine. Here, we report an efficient antisense-oligonucleotide (ASO) lipofection method to systematically evaluate and screen individual splicing events as therapeutic targets in pancreatic ductal adenocarcinoma organoids. This optimized delive","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-04-12T19:18:22.981Z","creation":"2026-04-07T13:17:41.282Z"},"accession":"S-EPMC11387002","cross_references":{"pubmed":["38716830"],"doi":["10.1089/nat.2023.0070"]}}